Qian Chu

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 23

Top Venues

British journal of cancer

Nature communications

Cancer medicine

Journal of oncology

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

China

Professor :: Department of Thoracic Oncology

Education History

Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

China

PHD

Publications

Jianjiao Ni, Xiaofei Wang, Lin Wu, Xinghao Ai, Qian Chu, Chengbo Han, Xiaorong Dong, Yue Zhou, Yechun Pang, Zhengfei Zhu
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial. Nature communications 15 (1) (2024)
Jianjiao Ni, Xiaofei Wang, Lin Wu, Xinghao Ai, Qian Chu, Chengbo Han, Xiaorong Dong, Yue Zhou, Yechun Pang, Zhengfei Zhu
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial. Nature communications 15 (1) (2024)
Fangfang Liu, Xuemei Zhang, Mengyao Lu, Chun Liu, Xiaodong Zhang, Qian Chu, Yuan Chen, Peng Zhang
The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy. Cancer medicine 13 (3) (2024)
Fangfang Liu, Xuemei Zhang, Mengyao Lu, Chun Liu, Xiaodong Zhang, Qian Chu, Yuan Chen, Peng Zhang
The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy. Cancer medicine 13 (3) (2024)
Zitian Huo, Yaqi Duan, Dongdong Zhan, Xizhen Xu, Nairen Zheng, Jing Cai, Ruifang Sun, Jianping Wang, Fang Cheng, Zhan Gao, Caixia Xu, Wanlin Liu, Yuting Dong, Sailong Ma, Qian Zhang, Yiyun Zheng, Liping Lou, Dong Kuang, Qian Chu, Jun Qin, Guoping Wang, Yi Wang
Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer. Genomics, proteomics & bioinformatics 22 (2) (2024)
Fangfang Liu, Xuemei Zhang, Mengyao Lu, Chun Liu, Xiaodong Zhang, Qian Chu, Yuan Chen, Peng Zhang
The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy. Cancer medicine 13 (3) (2024)
Jianjiao Ni, Xiaofei Wang, Lin Wu, Xinghao Ai, Qian Chu, Chengbo Han, Xiaorong Dong, Yue Zhou, Yechun Pang, Zhengfei Zhu
Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial. Nature communications 15 (1) (2024)
Zitian Huo, Yaqi Duan, Dongdong Zhan, Xizhen Xu, Nairen Zheng, Jing Cai, Ruifang Sun, Jianping Wang, Fang Cheng, Zhan Gao, Caixia Xu, Wanlin Liu, Yuting Dong, Sailong Ma, Qian Zhang, Yiyun Zheng, Liping Lou, Dong Kuang, Qian Chu, Jun Qin, Guoping Wang, Yi Wang
Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer. Genomics, proteomics & bioinformatics 22 (2) (2024)
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. British journal of cancer 130 (3) (2023)
Meng Jin, Zhihua Wang, Can Chen, Yongbiao Huang, Huixian Zhang, Bingliang Chen, Guoda Song, Dong Zhao, Limin Duan, Wei Liu, Haizhen Yang, Fang Yue, Peijun Liu, Xiang-Lin Yuan, Qian Chu, Jian-Bo Tian, Ke Hu
Genome-wide splicing QTL analysis identifies causal risk variants for non-small cell lung cancer. Cancer research (2023)
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. British journal of cancer 130 (3) (2023)
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. British journal of cancer 130 (3) (2023)
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. British journal of cancer (2023)
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Science advances 9 (21) (2023)
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. British journal of cancer 130 (3) (2023)
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. British journal of cancer 130 (3) (2023)
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Yingying Du, Jie Lin, Huaxin Duan, Huijuan Wang, Zemin Xiao, Hong Sun, Liyu Liu, Li Xu, Yan Xu, Fang Xu, Yi Kong, Xingxiang Pu, Kang Li, Qianzhi Wang, Jia Li, Baiyong Li, Yu Xia, Lin Wu
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. British journal of cancer 130 (3) (2023)
Shanshan Huang, Yongbiao Huang, Wanling Lin, Lei Wang, Yang Yang, Piao Li, Lei Xiao, Yuan Chen, Qian Chu, Xiang-Lin Yuan
Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder. Oxidative medicine and cellular longevity 2022 (2022)
Jingyu Chen, Chuhuai Wang, Weinuo Qu, Fangfang Liu, Zilin Zhou, Jiali Li, Qiongjie Hu, Qingguo Xie, Jinlin Wang, Qian Chu
CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer. Journal of oncology 2022 (2022)
Jingyu Chen, Chuhuai Wang, Weinuo Qu, Fangfang Liu, Zilin Zhou, Jiali Li, Qiongjie Hu, Qingguo Xie, Jinlin Wang, Qian Chu
CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer. Journal of oncology 2022 (2022)
Binghan Zhou, Wanling Lin, Yaling Long, Yunkai Yang, Huan Zhang, Kongming Wu, Qian Chu
Notch signaling pathway: architecture, disease, and therapeutics. Signal transduction and targeted therapy 7 (1) (2022)
Qingzhu Jia, Qian Chu, Anmei Zhang, Jing Yu, Fangfang Liu, Kaiyu Qian, Yu Xiao, Xue Wang, Ying Yang, Yi Zhao, Ji He, Guanghui Li, Yisong Y Wan, Conghua Xie, Bo Zhu
Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer. Communications biology 4 (1) (2021)
Man Zhang, Wei Yang, Peng Wang, Yu Deng, Yu-Ting Dong, Fang-Fang Liu, Rui Huang, Peng Zhang, Ya-Qi Duan, Xin-Dong Liu, Dandan Lin, Qian Chu, Bo Zhong
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nature communications 11 (1) (2020)

Qian Chu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Qian Chu